✦ LIBER ✦

A Randomized Prospective Trial of Oral Versus Intravenous Ganciclovir for Prophylaxis of Cytomegalovirus Infection and Disease in High-Risk Kidney Recipients

✍ Scribed by M. Nafar; M. Lessan Pezeshki; F. Farrokhi; B. Einollahi; F. Pour-Reza-Gholi; A. Firouzan; S. Farhangi

Book ID: 116931504
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 59 KB
Volume: 37
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2005.08.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized prospective controlled tria

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

✍ Reischig, Tomas; Opatrny, Karel; Bouda, Mirko; Treska, Vladislav; Jindra, Pavel; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 215 KB

A randomized prospective controlled tria

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

✍ Tomas Reischig; Karel Opatrny Jr.; Mirko Bouda; Vladislav Treska; Pavel Jindra; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 762 KB

Randomized controlled trial of oral ganc

Randomized controlled trial of oral ganciclovir versus intravenous ganciclovir for long-term prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients willi CMV-seropositive donors

✍ D. Winston; R.W. Busuttil 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 283 KB

Increased incidence of cytomegalovirus i

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis

✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos

Oral versus intravenous ganciclovir for

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

✍ J. Szer; S. Durrant; A. P. Schwarer; K. F. Bradstock; J. Gibson; C. Arthur; L. B 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Superior Efficacy of Oral Ganciclovir Ov

Superior Efficacy of Oral Ganciclovir Over Oral Acyclovir for Cytomegalovirus Prophylaxis in Kidney–Pancreas and Pancreas Alone Recipients

✍ T Somerville; G Hurst; R Alloway; A Gaber; M.H Shokouh-Amiri; R Stratta 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 156 KB